Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
cervical cancer
cervical screening
elimination
epidemiology
human immunodeficiency virus
human papillomavirus (HPV) vaccination
mathematical modelling
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
revised:
24
01
2021
received:
17
11
2020
accepted:
10
02
2021
pubmed:
27
2
2021
medline:
8
9
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
The World Health Organisation (WHO) has launched a strategic initiative for cervical cancer (CC) elimination which involves scaling up three interventions: human papillomavirus (HPV) vaccination, twice-lifetime HPV-screening screening and pre-cancer/cancer treatment by 2030. CC is challenging to control in countries with endemic human immunodeficiency virus (HIV), as women living with HIV (WLHIV) are at elevated risk of HPV infection, persistence and progression. This analysis estimated the impact of the elimination interventions on CC incidence and mortality but additionally considered more intensive screening for WLHIV, using Tanzania as an example. A dynamic HIV/HPV model was used to simulate the elimination strategy for vaccination, screening and pre-cancer/cancer treatment, with 3-yearly HPV-screening in WLHIV starting at age 25 years, in the context of sustained HIV control in Tanzania from 2020 to 2119. Without vaccination or HPV screening, CC incidence rates per 100 000 women are predicted to fall from 58.0 in 2020 to 41.6 (range: 39.1-44.7) in 2119, due to existing HIV control. HPV vaccination and twice-lifetime HPV-screening for the general population and 3-yearly screening for WLHIV, would reduce CC incidence to 1.3 (range: 1.3-2.5) by 2119, with elimination (<4/100 000) in 2076 (range: 2076-2092). CC mortality rates per 100 000 women are predicted to reach 1.1 (range: 1.1-2.1) with further reductions contingent on increased CC treatment access. Vaccination and 3-yearly HPV-screening for WLHIV is predicted to achieve elimination in the subgroup of WLHIV potentially as early as 2061 (range: 2061-2078), with a 2119 CC incidence rate of 1.7 (range: 1.7-3.3). Scaling-up vaccination and HPV-screening will substantially reduce CC incidence in Tanzania, with elimination predicted within a century. Three-yearly HPV-screening and HPV vaccination, at high coverage rates, would facilitate CC elimination among WLHIV, and thus accelerate elimination in the overall population.
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-306Informations de copyright
© 2021 Union for International Cancer Control.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-590.
Gavi the vaccine alliance. Human papillomavirus vaccine support 2020. https://www.gavi.org/types-support/vaccine-support/human-papillomavirus
World Health Organisation (WHO). A cervical cancer-free future: First-ever global commitment to eliminate a cancer Geneva, Switzerland; 2020. https://www.who.int/news/item/17-11-2020-a-cervical-cancer-free-future-first-ever-global-commitment-to-eliminate-a-cancer
Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS (London, England). 2018;32(6):795-808.
UNAIDS. Data Sheet - HIV Prevalence Population: Female Adults (15-49) Geneva, Switzerland; 2018. https://aidsinfo.unaids.org?did=554ca08005b5b281750af20a&r=world&t=2016&tb=d&bt=dnli&ts=0,0&tr=world&aid=577bfcca880284565dfd2ebf&sav=Population: Female adults (15-49)&tl=2
Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591-603.
Runge AS, Bernstein ME, Lucas AN, Tewari KS. Cervical cancer in Tanzania: a systematic review of current challenges in six domains. Gynecol Oncol Rep. 2019;29:40-47.
Bakiewicz A, Rasch V, Mwaiselage J, Linde DS. ‘The best thing is that you are doing it for yourself’ - perspectives on acceptability and feasibility of HPV self-sampling among cervical cancer screening clients in Tanzania: a qualitative pilot study. BMC Womens Health. 2020;20(1):65.
Cunningham MS, Skrastins E, Fitzpatrick R, et al. Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open. 2015;5(3):e005828.
De Vuyst H, Mugo NR, Franceschi S, et al. Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya. PLoS One. 2014;9(10):e111037.
Hall MT, Smith MA, Simms KT, Barnabas RV, Canfell K, Murray JM. The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: a modelling study. PLoS One. 2020;15(5):e0231388.
The United Republic of Tanzania Ministry of Health and Social Welfare. Report Number 23. Dar es Salaam, Tanzania: National AIDS Control Programme; 2013.
Ministry of Health CD, Gender, Elderly and Children (MoHCDGEC), Ministry of Health (MoH), National Bureau of Statistics (NBS), Office of the Chief Government Statistician (OCGS), ICF. Tanzania Demographic and Health Survey and Malaria Indicator Survey 2015-16; 2016.
World Health Organization (WHO). Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations. Policy Brief Geneva, Switzerland; 2020. https://apps.who.int/iris/rest/bitstreams/1295920/retrieve
Prodger JL, Kaul R. The biology of how circumcision reduces HIV susceptibility: broader implications for the prevention field. AIDS Res Ther. 2017;14(1):49.
Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346(15):1105-1112.
UNAIDS. Data Sheet - PEOPLE LIVING WITH HIV RECIEVING ART (%) Geneva, Switzerland: UNAIDS; 2018. https://aidsinfo.unaids.org?did=554c8ceac904ab29709ecd3b&r=world&t=null&tb=d&bt=dnli&ts=0,0&tr=world&aid=5ae071a462abc329969a8de1&sav=Population: All ages&tl=2
Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006;44(6):2141-2146.
Venturoli S, Cricca M, Bonvicini F, et al. Human papillomavirus DNA testing by PCR-ELISA and hybrid capture II from a single cytological specimen: concordance and correlation with cytological results. J Clin Virol. 2002;25(2):177-185.
Riethmuller D, Gay C, Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by hybrid capture II and polymerase chain reaction. Diagn Mol Pathol. 1999;8(3):157-164.
Kulmala SM, Syrjanen S, Shabalova I, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol. 2004;42(6):2470-2475.
Safaeian M, Herrero R, Hildesheim A, et al. Comparison of the SPF10-LiPA system to the hybrid capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol. 2007;45(5):1447-1454.
Wahlstrom C, Iftner T, Dillner J, Dillner L. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol. 2007;79(8):1169-1175.
Yamazaki H, Sasagawa T, Basha W, Segawa T, Inoue M. Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer. 2001;94(2):222-227.
Zuna RE, Wang SS, Rosenthal DL, Jeronimo J, Schiffman M, Solomon D. Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS). Cancer. 2005;105(5):253-262.
Soderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the hybrid capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol. 2005;43(7):3260-3266.
Simms KT, Steinberg J, Caruana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394-407.
Hall MT, Simms KT, Lew J-B, Smith MA, Saville M, Canfell K. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: example from Australia. PLoS One. 2018;13:e0185332.
PrEP Watch. Tanzania 2020. https://www.prepwatch.org/country/tanzania/
Harling G, Muya A, Ortblad KF, et al. HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: cross-sectional survey. BMJ Open. 2019;9(3):e023272.
Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2018;47:42-58.
Anaman-Torgbor J, Angmorterh SK, Dordunoo D, Ofori EK. Cervical cancer screening behaviours and challenges: a sub-Saharan Africa perspective. Pan Afr Med J. 2020;36:97.
Poli UR, Petignat P. Screen and treat with hpv testing in lmic countries. HPV World; 2020.
Mezei AK, Armstrong HL, Pedersen HN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017;141(3):437-446.
Sultana F, English DR, Simpson JA, et al. Home-based HPV self-sampling improves participation by never-screened and under-screened women: results from a large randomized trial (iPap) in Australia. Int J Cancer. 2016;139(2):281-290.
Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.
Coleman JS, Cespedes MS, Cu-Uvin S, et al. An insight into cervical cancer screening and treatment capacity in Sub Saharan Africa. J Low Genit Tract Dis. 2016;20(1):31-37.
Fitzpatrick MB, El-Khatib Z, Katzenstein D, Pinsky BA, Chirenje ZM, McCarty K. Community-based self-collected human papillomavirus screening in rural Zimbabwe. BMC Public Health. 2019;19(1):603.
World Health Organisation (WHO). Accelerate Cervical Cancer Elimination Initiative Geneva, Switzerland; 2020. https://www.who.int/reproductivehealth/publications/screening-cervical-pre-cancer-lesions-women-with-hiv/en/
Menon S, Rossi R, Kariisa M, Callens S. Determining the HPV vaccine schedule for a HIV-infected population in sub Saharan Africa, a commentary. Virology Journal. 2018;15:1. https://doi.org/10.1186/s12985-018-1039-y.
Lacey Charles JN. HPV vaccination in HIV infection. Papillomavirus Research. 2019;8:100174. https://doi.org/10.1016/j.pvr.2019.100174.